Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis
Authors
Keywords
Non-small-cell lung cancer, National Cancer Database, Immunotherapy, Stereotactic radiotherapy, Radioimmunotherapy
Journal
Radiation Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-28
DOI
10.1186/s13014-019-1222-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials
- (2018) Vivek Verma et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
- (2018) Gilberto Lopes et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy
- (2018) Taylor R Cushman et al. Immunotherapy
- Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.
- (2018) Willemijn Theelen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using the National Cancer Database for Outcomes Research
- (2017) Daniel J. Boffa et al. JAMA Oncology
- A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger?
- (2017) Raffaella Marconi et al. PLoS One
- Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER–Medicare Database
- (2016) Chun Chieh Lin et al. ANNALS OF SURGICAL ONCOLOGY
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- (2016) Daniel R Gomez et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- (2015) A. Filatenkov et al. CLINICAL CANCER RESEARCH
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer
- (2015) Kenneth D. Westover et al. LUNG CANCER
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer
- (2014) Puneeth Iyengar et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
- (2009) Y. Lee et al. BLOOD
- Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
- (2008) S. Ramalingam et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now